FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
出版年份 2016 全文链接
标题
FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer
作者
关键词
-
出版物
WORLD JOURNAL OF GASTROENTEROLOGY
Volume 22, Issue 31, Pages 6987
出版商
Baishideng Publishing Group Inc.
发表日期
2016-08-15
DOI
10.3748/wjg.v22.i31.6987
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Hepatocyte growth factor inhibition: a novel therapeutic approach in pancreatic cancer
- (2016) Srinivasa P Pothula et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Toward stratification of patients with pancreatic cancer: Past lessons from traditional approaches and future applications with physical biomarkers
- (2016) Eugene J. Koay et al. CANCER LETTERS
- Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib
- (2016) Ganji Purnachandra Nagaraju et al. EUROPEAN JOURNAL OF CANCER
- Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial
- (2016) Timothy M Nywening et al. LANCET ONCOLOGY
- A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma
- (2016) Andrew H. Ko et al. PANCREAS
- MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulatingPTENandPDCD4
- (2016) Xueju Wei et al. Cancer Medicine
- T Cells Engineered against a Native Antigen Can Surmount Immunologic and Physical Barriers to Treat Pancreatic Ductal Adenocarcinoma
- (2015) Ingunn M. Stromnes et al. CANCER CELL
- RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics
- (2015) Myron G. Best et al. CANCER CELL
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma
- (2015) A. H. Ko et al. CLINICAL CANCER RESEARCH
- The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)
- (2015) F. Vena et al. CLINICAL CANCER RESEARCH
- SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
- (2015) M. Hidalgo et al. CLINICAL CANCER RESEARCH
- Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial
- (2015) L. A. Chantrill et al. CLINICAL CANCER RESEARCH
- Human equilibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine – Results from the CONKO-001 trial
- (2015) M. Sinn et al. EUROPEAN JOURNAL OF CANCER
- High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis
- (2015) Cindy Neuzillet et al. HISTOPATHOLOGY
- Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
- (2015) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
- (2015) Dung T. Le et al. JOURNAL OF CLINICAL ONCOLOGY
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas
- (2015) Mie Grunnet et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
- Metastatic pancreatic cancer: Is there a light at the end of the tunnel?
- (2015) Vanja Vaccaro WORLD JOURNAL OF GASTROENTEROLOGY
- MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603
- (2015) Liza C. Villaruz et al. Clinical Epigenetics
- Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma
- (2015) Michela Capello et al. JNCI-Journal of the National Cancer Institute
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid tumors
- (2014) A. W. Tolcher et al. ANNALS OF ONCOLOGY
- Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
- (2014) E Van Cutsem et al. BRITISH JOURNAL OF CANCER
- Pancreatic Cancer Stroma: Friend or Foe?
- (2014) Jesse Gore et al. CANCER CELL
- Stromal Elements Act to Restrain, Rather Than Support, Pancreatic Ductal Adenocarcinoma
- (2014) Andrew D. Rhim et al. CANCER CELL
- The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell–endothelial cell interactions: antiangiogenic implications in pancreatic cancer
- (2014) Mishaal B. Patel et al. CARCINOGENESIS
- Response to GEMOX plus erlotinib in pancreatic cancer is associated with ERCC1 overexpression
- (2014) Thorsten Fuereder et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- miR-145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6
- (2014) Xiaolan Zhu et al. INTERNATIONAL JOURNAL OF CANCER
- Stromal MicroRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer
- (2014) Timothy R. Donahue et al. JOURNAL OF SURGICAL ONCOLOGY
- Elevation of circulating branched-chain amino acids is an early event in human pancreatic adenocarcinoma development
- (2014) Jared R Mayers et al. NATURE MEDICINE
- The clinical development of MEK inhibitors
- (2014) Yujie Zhao et al. Nature Reviews Clinical Oncology
- miR-345 in Metastatic Colorectal Cancer: A Non-Invasive Biomarker for Clinical Outcome in Non-KRAS Mutant Patients Treated with 3rd Line Cetuximab and Irinotecan
- (2014) Jakob V. Schou et al. PLoS One
- Tissue MicroRNAs as Predictors of Outcome in Patients with Metastatic Colorectal Cancer Treated with First Line Capecitabine and Oxaliplatin with or without Bevacizumab
- (2014) Mogens K. Boisen et al. PLoS One
- SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients
- (2014) Neil Desai et al. Translational Oncology
- Personalising pancreas cancer treatment: When tissue is the issue
- (2014) Katrin M Sjoquist WORLD JOURNAL OF GASTROENTEROLOGY
- Recent studies of 5-fluorouracil resistance in pancreatic cancer
- (2014) Wei-Bin Wang WORLD JOURNAL OF GASTROENTEROLOGY
- Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer
- (2014) Ingrid Garajová et al. Biomed Research International
- Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
- (2013) Jun-Eul Hwang et al. BMC CANCER
- Treatment of HER2-positive breast cancer
- (2013) Maria Cristina Figueroa-Magalhães et al. BREAST
- Stromal disrupting effects of nab-paclitaxel in pancreatic cancer
- (2013) R Alvarez et al. BRITISH JOURNAL OF CANCER
- Crizotinib Inhibits Metabolic Inactivation of Gemcitabine in c-Met-driven Pancreatic Carcinoma
- (2013) A. Avan et al. CANCER RESEARCH
- A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma
- (2013) G. L. Beatty et al. CLINICAL CANCER RESEARCH
- Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer
- (2013) Philippe Rougier et al. EUROPEAN JOURNAL OF CANCER
- MicroRNAs Cooperatively Inhibit a Network of Tumor Suppressor Genes to Promote Pancreatic Tumor Growth and Progression
- (2013) Adam E. Frampton et al. GASTROENTEROLOGY
- Prognostic factors in gemcitabine-cisplatin polychemotherapy regimens in pancreatic cancer:XPD-Lys751Glnpolymorphism strikes back
- (2013) Amir Avan et al. INTERNATIONAL JOURNAL OF CANCER
- miRNA27a Is a Biomarker for Predicting Chemosensitivity and Prognosis in Metastatic or Recurrent Gastric Cancer
- (2013) Dingzhi Huang et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Randomized, Multicenter, Phase II Study of CO-101 Versus Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: Including a Prospective Evaluation of the Role of hENT1 in Gemcitabine or CO-101 Sensitivity
- (2013) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- nab-Paclitaxel mechanisms of action and delivery
- (2013) Denise A. Yardley JOURNAL OF CONTROLLED RELEASE
- Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial
- (2013) William Greenhalf et al. JNCI-Journal of the National Cancer Institute
- miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase
- (2013) Yunfei Zhou et al. Molecular Oncology
- Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment
- (2013) J.B. Kjersem et al. Molecular Oncology
- High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer
- (2013) Mads H. Rasmussen et al. Molecular Oncology
- ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
- (2013) Luc Friboulet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Meta-Analysis of Gemcitabine Biomarkers in Patients With Pancreaticobiliary Cancers
- (2013) Christina H. Wei et al. PANCREAS
- Modified FOLFIRINOX Regimen With Improved Safety and Maintained Efficacy in Pancreatic Adenocarcinoma
- (2013) Hemchandra Mahaseth et al. PANCREAS
- CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer
- (2013) A. Neesse et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
- (2013) C Hage et al. Cell Death & Disease
- The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer
- (2013) Thierry Conroy et al. Current Oncology Reports
- The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms
- (2012) S. Caponi et al. ANNALS OF ONCOLOGY
- BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer
- (2012) A. Gonçalves et al. ANNALS OF ONCOLOGY
- Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer
- (2012) J Harder et al. BRITISH JOURNAL OF CANCER
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma
- (2012) Paolo P. Provenzano et al. CANCER CELL
- The Pancreas Cancer Microenvironment
- (2012) C. Feig et al. CLINICAL CANCER RESEARCH
- Molecular Targets of Gemcitabine Action: Rationale for Development of Novel Drugs and Drug Combinations
- (2012) Maha Elnaggar et al. CURRENT PHARMACEUTICAL DESIGN
- Does gemcitabine-based combination therapy improve the prognosis of unresectable pancreatic cancer?
- (2012) Chen Sun WORLD JOURNAL OF GASTROENTEROLOGY
- nab -Paclitaxel Potentiates Gemcitabine Activity by Reducing Cytidine Deaminase Levels in a Mouse Model of Pancreatic Cancer
- (2012) Kristopher K. Frese et al. Cancer Discovery
- Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer
- (2011) Troels K. Bergmann et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- c-Met Is a Marker of Pancreatic Cancer Stem Cells and Therapeutic Target
- (2011) Chenwei Li et al. GASTROENTEROLOGY
- Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil
- (2011) Hayato Fujita INTERNATIONAL JOURNAL OF ONCOLOGY
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
- (2011) György Bodoky et al. INVESTIGATIONAL NEW DRUGS
- Gemcitabine Plusnab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial
- (2011) Daniel D. Von Hoff et al. JOURNAL OF CLINICAL ONCOLOGY
- Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study
- (2011) Hedy L Kindler et al. LANCET ONCOLOGY
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between DNA-repair polymorphisms and survival in pancreatic cancer patients treated with combination chemotherapy
- (2011) Elisa Giovannetti et al. PHARMACOGENOMICS
- MicroRNA-21 in Pancreatic Cancer: Correlation with Clinical Outcome and Pharmacologic Aspects Underlying Its Role in the Modulation of Gemcitabine Activity
- (2010) Elisa Giovannetti et al. CANCER RESEARCH
- Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)
- (2010) Hedy Lee Kindler et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205
- (2010) Philip A. Philip et al. JOURNAL OF CLINICAL ONCOLOGY
- RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
- (2010) Georgia Hatzivassiliou et al. NATURE
- Role of primary miRNA polymorphic variants in metastatic colon cancer patients treated with 5-fluorouracil and irinotecan
- (2010) V Boni et al. PHARMACOGENOMICS JOURNAL
- Identification of MicroRNA-21 as a Biomarker for Chemoresistance and Clinical Outcome Following Adjuvant Therapy in Resectable Pancreatic Cancer
- (2010) Jin-Hyeok Hwang et al. PLoS One
- Phase III Trial of Bevacizumab in Combination With Gemcitabine and Erlotinib in Patients With Metastatic Pancreatic Cancer
- (2009) Eric Van Cutsem et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (fixed-dose rate infusion) Compared With Gemcitabine (30-minute infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group
- (2009) Elizabeth Poplin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
- (2009) David Cunningham et al. JOURNAL OF CLINICAL ONCOLOGY
- MicroRNA-200c mitigates invasiveness and restores sensitivity to microtubule-targeting chemotherapeutic agents
- (2009) D. R. Cochrane et al. MOLECULAR CANCER THERAPEUTICS
- Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer
- (2009) K. P. Olive et al. SCIENCE
- Allogeneic Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Immunotherapy Alone or in Sequence with Cyclophosphamide for Metastatic Pancreatic Cancer: A Pilot Study of Safety, Feasibility, and Immune Activation
- (2008) D. Laheru et al. CLINICAL CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
- Potential of Spice-Derived Phytochemicals for Cancer Prevention
- (2008) Bharat Aggarwal et al. PLANTA MEDICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now